MADD Antibody | 1150

MADD Antibody | 1150 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: MADD antibody was raised against a peptide corresponding to amino acids near the carboxy terminus of human MADD.
The immunogen is located within the last 50 amino acids of MADD.

Research Area: Signal Transduction

Tested Application: E, WB, ICC, IF

Application: MADD antibody can be used for detection of MADD by Western blot at 1 - 2 mg/mL. 200 to 220 kDa bands should be detected. Antibody can also be used for immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human and mouse samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1201 - HeLa Cell Lysate

Positive Control 2: Cat. No. 1212 - 3T3 Cell Lysate

Positive Control 3: Cat. No. 10-901 - Human Spleen Tissue Slide

Positive Control 4: Cat. No. 17-001 - HeLa Cell Slide

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 200 to 220 kDa

Validation: N/A

Isoform: N/A

Purification: MADD Antibody is Antibody is DEAE purified.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: MADD Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/ml

Storage Condition: MADD antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: MADD Antibody: DENN, IG20, RAB3GEP, DENN, KIAA0358, MAP kinase-activating death domain protein, Differentially expressed in normal and neoplastic cells

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: MADD Antibody: MAP kinase-activating death domain protein (MADD) was initially identified as the type 1 tumor necrosis factor receptor (TNFR1) associated protein though their death domains. Overexpression of MADD activates MAP kinases ERK and JNK and induces the phosphorylation of cytosolic phospholipase A2. MADD shares 98% identity with DENN (for differentially expressed in neoplastic vs. normal cells), which was recently identified as a substrate for c-jun N-terminal kinase 3 (JNK3). MADD has greater than 94% overall identity to a GDP/GTP exchange protein Rab3-GEP. MADD is 87% identical to KIAA0358, a brain protein of unknown function. Identification of MADD as a component of the TNFR1 signaling complex and the similarity between MADD and Rab3-GEP provides a connection between TNFR1 activation and downstream MAP kinase activity through a guanine-nucleotide exchange protein.